KR101881886B1 - Alk 키나제 억제제, 이의 제조방법 및 이의 용도 - Google Patents

Alk 키나제 억제제, 이의 제조방법 및 이의 용도 Download PDF

Info

Publication number
KR101881886B1
KR101881886B1 KR1020167036475A KR20167036475A KR101881886B1 KR 101881886 B1 KR101881886 B1 KR 101881886B1 KR 1020167036475 A KR1020167036475 A KR 1020167036475A KR 20167036475 A KR20167036475 A KR 20167036475A KR 101881886 B1 KR101881886 B1 KR 101881886B1
Authority
KR
South Korea
Prior art keywords
inhabitor
preparation
alk kinase
alk
kinase
Prior art date
Application number
KR1020167036475A
Other languages
English (en)
Other versions
KR20170007483A (ko
Inventor
지아치앙 동
보위 종
홍빈 위엔
취엔 스
샤오송 추
더이 장
뤼하오 장
Original Assignee
베이징 피어 바이오테크놀로지 리미티드 라이어빌리티 컴페니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베이징 피어 바이오테크놀로지 리미티드 라이어빌리티 컴페니 filed Critical 베이징 피어 바이오테크놀로지 리미티드 라이어빌리티 컴페니
Publication of KR20170007483A publication Critical patent/KR20170007483A/ko
Application granted granted Critical
Publication of KR101881886B1 publication Critical patent/KR101881886B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
KR1020167036475A 2014-05-30 2015-05-29 Alk 키나제 억제제, 이의 제조방법 및 이의 용도 KR101881886B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201410238263 2014-05-30
CN201410238263.6 2014-05-30
PCT/CN2015/080273 WO2015180685A1 (zh) 2014-05-30 2015-05-29 Alk激酶抑制剂及其制备方法和应用

Publications (2)

Publication Number Publication Date
KR20170007483A KR20170007483A (ko) 2017-01-18
KR101881886B1 true KR101881886B1 (ko) 2018-07-25

Family

ID=54698131

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167036475A KR101881886B1 (ko) 2014-05-30 2015-05-29 Alk 키나제 억제제, 이의 제조방법 및 이의 용도

Country Status (9)

Country Link
US (1) US10023593B2 (ko)
EP (1) EP3150592B1 (ko)
JP (1) JP6339241B2 (ko)
KR (1) KR101881886B1 (ko)
CN (1) CN105294654B (ko)
AU (1) AU2015266453C1 (ko)
HK (1) HK1219952A1 (ko)
WO (1) WO2015180685A1 (ko)
ZA (1) ZA201700021B (ko)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018508524A (ja) * 2015-03-04 2018-03-29 ノバルティス アーゲー ピリミジン誘導体およびそれらの中間体を調製する化学的方法
CN106866684B (zh) * 2015-12-10 2020-06-09 吴耀东 用于治疗肿瘤的大环衍生物
CN106083595A (zh) * 2016-06-08 2016-11-09 常州安迪沃克医药科技有限公司 抗癌药物色瑞替尼中间体2‑氯(溴)‑4‑氟‑5‑硝基甲苯的合成方法
CN107540666B (zh) * 2016-06-27 2023-03-24 杭州雷索药业有限公司 苯并呋喃吡唑胺类蛋白激酶抑制剂
CN110563656A (zh) * 2018-06-06 2019-12-13 四川大学 嘧啶类小分子化合物及在制备抗分枝杆菌药物中的用途
CN111362922A (zh) * 2018-12-26 2020-07-03 上海喆邺生物科技有限公司 2,4-二氨基嘧啶衍生物及其用途
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN113993859A (zh) 2019-06-25 2022-01-28 益方生物科技(上海)股份有限公司 杂环化合物、其制备方法及其使用方法
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2648170A1 (en) * 2006-04-10 2007-10-18 Boehringer Ingelheim International Gmbh 2, 4-diaminopyrimidine derivatives and their use for the treatment of cancer
US8148391B2 (en) * 2006-10-23 2012-04-03 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors
EA017252B1 (ru) * 2007-08-28 2012-11-30 Айрм Ллк Производные 2-бифениламино-4-аминопиримидина в качестве ингибиторов киназ
WO2009032669A2 (en) * 2007-09-06 2009-03-12 Polyone Corporation Soft, shock-damping thermoplastic elastomers
DK2300013T3 (en) * 2008-05-21 2017-12-04 Ariad Pharma Inc PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS
UY31929A (es) * 2008-06-25 2010-01-05 Irm Llc Compuestos y composiciones como inhibidores de cinasa
CN102317268A (zh) * 2008-06-25 2012-01-11 Irm责任有限公司 作为激酶抑制剂的2-联苯基氨基-4-氨基嘧啶衍生物
UA101057C2 (en) * 2008-06-25 2013-02-25 Айерем Элелси Pyrimidine derivatives as kinase inhibitors
EP2552214A4 (en) * 2010-03-26 2013-10-16 Glaxo Group Ltd PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS
CN104672214B (zh) * 2013-12-03 2019-04-12 上海翰森生物医药科技有限公司 具有alk抑制活性的化合物及其制备与用途

Also Published As

Publication number Publication date
BR112016028017A2 (pt) 2023-01-10
CN105294654A (zh) 2016-02-03
WO2015180685A1 (zh) 2015-12-03
AU2015266453B2 (en) 2018-04-12
KR20170007483A (ko) 2017-01-18
HK1219952A1 (zh) 2017-04-21
US10023593B2 (en) 2018-07-17
JP2017516825A (ja) 2017-06-22
US20170247392A1 (en) 2017-08-31
JP6339241B2 (ja) 2018-06-06
ZA201700021B (en) 2018-12-19
AU2015266453A1 (en) 2017-01-05
EP3150592B1 (en) 2023-08-30
AU2015266453C1 (en) 2018-09-13
CN105294654B (zh) 2018-01-09
EP3150592A1 (en) 2017-04-05
EP3150592A4 (en) 2018-01-24

Similar Documents

Publication Publication Date Title
AU2015330506B2 (en) EGFR inhibitor, and preparation and application thereof
EP3240569A4 (en) Anti-cd47 antibodies and uses thereof
EP3186277A4 (en) Antibodies, compositions, and uses
EP3183349A4 (en) Methods for preparing rebaudioside i and uses
EP3099677A4 (en) Diaminopyrimidine benzenesulfone derivatives and uses thereof
EP3104865A4 (en) Micro-organoids, and methods of making and using the same
EP3099171A4 (en) Dihydropteridinone derivatives and uses thereof
KR101881886B1 (ko) Alk 키나제 억제제, 이의 제조방법 및 이의 용도
EP3122344A4 (en) TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
EP3140305A4 (en) Novel compositions, uses and methods for making them
EP3200823A4 (en) Multivalent meditopes, meditope-binding antibodies and uses thereof
EP3122346A4 (en) Trka kinase inhibitors, compositions and methods thereof
EP3230132A4 (en) Smartkey apparatuses, methods and systems
EP3246327A4 (en) 3-acetylenyl-pyrazole-pyrimidine derivative, and preparation method therefor and uses thereof
EP3110895A4 (en) Polysilocarb materials, methods and uses
EP3115361A4 (en) Heterocyclic compounds, and preparation method and use thereof
EP3137168A4 (en) Substituted 4-phenylpiperidines, their preparation and use
EP3272063A4 (en) Host-storage authentication
EP3369734A4 (en) KINASEINHIBITOR AND METHOD OF PREPARATION AND PHARMACEUTICAL USE THEREOF
EP3177147A4 (en) Dihydropteridinone derivatives and uses thereof
EP3248188B8 (en) Authentication method
EP3372596A4 (en) METHOD FOR THE PRODUCTION OF TEDIZOLIDE, TEDIZOLIDE INTERMEDIATE PRODUCTION AND METHOD OF MANUFACTURING THEREOF
EP3114315A4 (en) Geosteering systems and methods thereof
EP3189477A4 (en) Authentication system
EP3388065A4 (en) SOLID DISPERSION OF DECOQUINATE, PREPARATION METHOD AND USE THEREOF

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
GRNT Written decision to grant